Palatin Technologies, Inc.
PTNHealthcare|Biotechnology|US
$6.27
+0.56 (+9.81%)
Tangible Book / Share
$1.71
Cash / Share
$1.91
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06565611 A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Obesity | P2 | Active | 108 | RCT, Double-blind | bremelanotide, tirzepatide |
| NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) | Ulcerative Colitis, Ulcerative Colitis Acute | P2 | Active | 16 | RCT, Double-blind | PL8177 Placebo, PL8177 |
| NCT02338960 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | Hypoactive Sexual Desire Disorder | P3 | Completed | 714 | RCT, Double-blind | Bremelanotide, Placebo |
| NCT05201170 A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye | Dry Eye, Dry Eye Syndromes | P3 | Completed | 575 | RCT, Double-blind | Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution |
| NCT02333071 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | Hypoactive Sexual Desire Disorder | P3 | Completed | 723 | RCT, Double-blind | Bremelanotide |
| NCT00425256 Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) | Sexual Arousal Disorder | P2 | Completed | — | RCT, Double-blind | Bremelanotide |
| NCT01304628 Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma | Asthma | P2 | Withdrawn | — | RCT, Double-blind | PL-3994 |
| NCT05709444 A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease | Kidney Disease | P2 | Completed | 16 | Open-label | Bremelanotide, RAAS inhibition therapy |
| NCT00686803 Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension | Hypertension | P2 | Completed | 21 | RCT, Double-blind | PL3994, Placebo |
| NCT04268069 Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye | Dry Eye Disease | P2 | Completed | 160 | RCT, Double-blind | PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution |
| NCT01382719 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder | Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder | P2 | Completed | 612 | RCT, Double-blind | bremelanotide |
| NCT04318145 Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects | Heart Failure With Preserved Ejection Fraction | P2 | Terminated | 15 | Open-label | PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose |